The RTS,S vaccine candidate for malaria

@article{Regules2011TheRV,
  title={The RTS,S vaccine candidate for malaria},
  author={Jason A. Regules and James F. Cummings and Christian Ockenhouse},
  journal={Expert Review of Vaccines},
  year={2011},
  volume={10},
  pages={589 - 599}
}
Malaria continues to be a worldwide leading cause of morbidity and mortality, and the development of an effective malaria vaccine remains a research imperative. Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine formulation. Throughout its development, increasingly more effective adjuvants have been key in improving the potency of the vaccine. RTS,S-based vaccine formulations have been… Expand
Profiling the host response to malaria vaccination and malaria challenge
TLDR
This review outlines the background, existing studies, limits and opportunities for gene expression studies to accelerate malaria vaccine research, and outlines the availability of experimental sporozoite challenge in humans to test candidate malaria vaccines. Expand
Immune mechanisms in malaria: new insights in vaccine development
TLDR
It is argued that rational design of more effective malaria vaccines will be accelerated by a better understanding of the immune effector mechanisms involved in parasite regulation, control and elimination. Expand
Implementation of RTS,S/AS01 Malaria Vaccine--The Need for Further Evidence.
TLDR
RTS,S/AS01, a recombinant vaccine against the pre-erythrocytic stage of the parasite in which regions of P. falciparum circumsporozoite protein are fused to hepatitis B surface antigen is presented. Expand
A review of combination adjuvants for malaria vaccines: a promising approach for vaccine development.
TLDR
This review paper outlines some of the best known combination adjuvants used in malaria subunit vaccines, focusing on their proposed mechanisms of action, their immunological properties, and their notable results. Expand
Challenges and responses in human vaccine development.
TLDR
Gene expression profiles and immune parameters in patients, vaccinees and healthy controls have formed the basis for biosignatures that will provide guidelines for future vaccine design, and reverse and structural vaccinology have revealed novel antigen candidates and molecular immunology has led to the formulation of promising adjuvants. Expand
Progress in Vaccine Development
  • P. Moyle
  • Medicine, Biology
  • Current protocols in microbiology
  • 2015
TLDR
This unit provides an overview of the components that are used for the development of modern vaccines including an introduction to different vaccine types; techniques for identifying subunit antigens; vaccine delivery systems; and immunostimulatory agents (‘adjuvants’), which are fundamental for theDevelopment of effective subunit vaccines. Expand
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
TLDR
It is demonstrated that in BALB/c mice R21 is immunogenic at very low doses and when administered with the adjuvants Abisco-100 and Matrix-M it elicits sterile protection against transgenic sporozoite challenge. Expand
The malaria vaccine--status quo 2013.
  • D. Heppner
  • Medicine
  • Travel medicine and infectious disease
  • 2013
TLDR
Targets for a vaccine to protect against placental malaria, the leading remediable cause of low birth weight infants in Africa, have been identified and renewed efforts are underway to develop a practical attenuated-sporozoite vaccine to recapture the promise of David Clyde's experiment. Expand
Emerging drugs for malaria
TLDR
The lack of new treatments for severe malaria and the predominance of artemisinin-based combination therapy for uncomplicated malaria is concerning, and future research should be directed towards the discovery of new therapeutic principles. Expand
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
TLDR
R21/MM appears safe and very immunogenic in African children, and shows promising high-level efficacy in this double-blind, randomised, controlled, phase 2b trial. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique
TLDR
The RTS,S/AS02A candidate malaria vaccine has been shown to be safe and immunogenic in previous studies in adults and staggered dose‐escalation studies in children in The Gambia, and genetic features and the intensity of malaria transmission may modify the safety and immune response. Expand
Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
TLDR
RTS,S/AS01B is a safe and immunogenically superior formulation for cellular responses, in comparison with the RTS, S/AS02A-standard. Expand
Adjuvants for malaria vaccines
TLDR
The current state of adjuvant research and development as it pertains to effective malaria vaccines is outlined. Expand
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial
TLDR
The results show development of an effective vaccine against malaria is feasible and the RTS,S/AS02A vaccine was safe, well tolerated, and immunogenic. Expand
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.
TLDR
RTS,S/AS01E shows promise as a candidate malaria vaccine as compared with rabies vaccine in children in Kilifi, Kenya, and Korogwe, Tanzania, a target population for vaccine licensure. Expand
Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
TLDR
The use of the RTS,S/AS02D vaccine in infants had a promising safety profile, did not interfere with the immunologic responses to coadministered EPI antigens, and reduced the incidence of malaria infection. Expand
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.
TLDR
RTS,S/AS01(E) integrated in the EPI showed a favorable safety and immunogenicity evaluation, and rates of response to polio 3 antigens were comparable between groups. Expand
A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.
TLDR
It is concluded that the RTS,S/SBAS2 vaccine induces no significant toxicity in this semi-immune population and produces significant increases in antibody titers to CSP. Expand
A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
TLDR
A recombinant vaccine based on fusion of the circumsporozoite protein and HBsAg plus a potent adjuvant can protect against experimental challenge with P. falciparum malaria. Expand
Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.
TLDR
RTS,S/AS02A is safe and similarly immunogenic in malaria-exposed African adults of different ethnicity in different transmission settings, and these safety and immunogenicity data from adults in hyperendemic Kenya are comparable to data reported earlier from two trials in west African adults in hypo-endemic and meso- endemic areas of The Gambia. Expand
...
1
2
3
4
5
...